Immix Biopharma, Inc.
US ˙ NasdaqCM ˙ US45258H1068

SecurityIMMX / Immix Biopharma, Inc.
InstitutionNorthern Trust Corp
Latest Disclosed Ownership138,232 shares
Latest Disclosed Value $ 1,259,294
Northern Trust Corp reports 37.33% increase in ownership of IMMX / Immix Biopharma, Inc.

On May 14, 2026 - Northern Trust Corp filed a 13F-HR form disclosing ownership of 138,232 shares of Immix Biopharma, Inc. (US:IMMX) valued at $1,259,294 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 100,658 shares of Immix Biopharma, Inc.. This represents a change in shares of 37.33% during the quarter. The current value of the position is $1,093,415 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-14 2026-03-31 13F IMMIX BIOPHARMA COM 45258H106 138,232 37,574 37.33 1,259 139.35 0.0000
2026-02-17 2025-12-31 13F IMMIX BIOPHARMA COM 45258H106 100,658 11,357 12.72 526 182.80 0.0000
2025-11-14 2025-09-30 13F IMMIX BIOPHARMA COM 45258H106 89,301 -4,587 -4.89 187 -4.12 0.0000
2025-08-13 2025-06-30 13F IMMIX BIOPHARMA COM 45258H106 93,888 -1,374 -1.44 194 21.25 0.0000
2025-05-13 2025-03-31 13F IMMIX BIOPHARMA COM 45258H106 95,262 56,348 144.80 160 88.24 0.0000
2025-02-14 2024-12-31 13F IMMIX BIOPHARMA COM 45258H106 38,914 0 0.00 86 49.12 0.0000
2024-11-13 2024-09-30 13F IMMIX BIOPHARMA COM 45258H106 38,914 0 0.00 58 -25.97 0.0000
2024-08-14 2024-06-30 13F IMMIX BIOPHARMA COM 45258H106 38,914 0 0.00 77 -35.29 0.0000
2024-05-14 2024-03-31 13F IMMIX BIOPHARMA COM 45258H106 38,914 14,536 59.63 119 -29.17 0.0000
2024-02-13 2023-12-31 13F IMMIX BIOPHARMA COM 45258H106 24,378 24,378 169 0.0000
2023-05-15 2023-03-31 13F IMMIX BIOPHARMA COM 45258H106 0 -19,151 -100.00 0 -100.00
2023-02-13 2022-12-31 13F IMMIX BIOPHARMA COM 45258H106 19,151 0 0.00 44 65.38 0.0000
2022-11-14 2022-09-30 13F IMMIX BIOPHARMA COM 45258H106 19,151 19,151 26 0.0000
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.